Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dow Jones Industrial Average ETF (DIA) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Dow Jones Industrial Average ETFTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Dow Jones Industrial Average ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.41 (market cap $5.07B), while Dow Jones Industrial Average ETF trades at $537.1. Which is the better fit depends on your goals.

ACADDIA
Market Cap
$5.07B
Sector
Health
52-Week High
$29.41$542.79
52-Week Low
$20.06$444.64
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Dow Jones Industrial Average ETF

DIA (SPDR Dow Jones Industrial Average ETF) trades at $538.46, showing minimal daily movement with a slight 0.1% decline. The technical outlook remains bullish with strong moving average signals, though RSI levels suggest potential overbought conditions. Recent dividend distributions highlight the fund's income-generating capabilities, with upcoming payments scheduled through mid-2026.

The ETF offers diversified exposure to Dow Jones blue-chip stocks amid positive market breadth. Key risks include market volatility and geopolitical tensions affecting broad indices. Analyst sentiment remains constructive given the fund's defensive positioning and institutional inflows into core index heavyweights.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA